Legend Biotech (LEGN) Share-based Compensation (2020 - 2025)

Legend Biotech's Share-based Compensation history runs 6 years deep, the most recent figure standing at $15.0 million for Q3 2025.

• Quarterly Share-based Compensation fell 0.64% year-over-year to $15.0 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $63.0 million (down 7.48% YoY) and the FY2024 annual result came in at $68.9 million, up 44.59% from the prior year.
• Share-based Compensation was $15.0 million for Q3 2025 at Legend Biotech, down from $18.7 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $21.7 million in Q2 2024 and bottomed at $2.3 million in Q1 2021.
• A 5-year average of $11.6 million and a median of $12.4 million in 2023 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2021 — Share-based Compensation soared 573.64% — and 2025, when it fell 14.74%.
• Legend Biotech's Share-based Compensation stood at $5.2 million in 2021, then surged by 72.56% to $9.0 million in 2022, then surged by 40.3% to $12.6 million in 2023, then rose by 6.35% to $13.4 million in 2024, then grew by 12.15% to $15.0 million in 2025.
• Business Quant data shows LEGN's Share-based Compensation at $15.0 million in Q3 2025, $18.7 million in Q2 2025, and $15.9 million in Q1 2025.